LISA MILLER: Open Payments
NPI 1093049173 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,631 in 49 payments from 20 companies in 2025. Trend: 2023 $2,112 · 2024 $1,767 · 2025 $2,631
Food & beverage: $2,521Education: $109
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $450 |
| Amgen Inc. | 4 | $254 |
| Teva Pharmaceuticals USA, Inc. | 2 | $210 |
| UCB, Inc. | 5 | $190 |
| COLOPLAST CORP | 1 | $167 |
| Janssen Pharmaceuticals, Inc | 1 | $150 |
| GENZYME CORPORATION | 1 | $129 |
| Grifols USA, LLC | 1 | $129 |
| Vanda Pharmaceuticals Inc. | 1 | $125 |
| Calliditas Therapeutics US Inc. | 1 | $125 |
Products named: QULIPTA, Titan, UPLIZNA, Fintepla, SPRAVATO, FABRAZYME, Gamunex-C, PONVORY.
Industry payments across LA — which companies pay providers there.
